DOUGLAS PHARMACEUTICALS LTD has a total of 49 patent applications. It increased the IP activity by 800.0%. Its first patent ever was published in 2003. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and Australia. Its main competitors in its focus markets pharmaceuticals are DIAKINE THERAPEUTICS INC, LUXENA PHARMACEUTICALS INC and ALAN LABORATORIES INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 9 | |
#2 | United States | 7 | |
#3 | Australia | 5 | |
#4 | Canada | 5 | |
#5 | EPO (European Patent Office) | 5 | |
#6 | United Kingdom | 5 | |
#7 | China | 4 | |
#8 | Brazil | 3 | |
#9 | Singapore | 3 | |
#10 | Republic of Korea | 1 | |
#11 | Mexico | 1 | |
#12 | New Zealand | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Hampson Ian | 13 |
#2 | Hampson Lynne | 13 |
#3 | Glue Paul William | 12 |
#4 | Binnie Fergus Cameron | 12 |
#5 | Vos Marten Geert | 11 |
#6 | Surman Peter William | 11 |
#7 | Medlicott Natalie June | 10 |
#8 | Surman Peter | 10 |
#9 | Mcleod Andrew Douglas | 5 |
#10 | Mak Wai Bik | 5 |
Publication | Filing date | Title |
---|---|---|
US2021052517A1 | Extended release pharmaceutical formulation | |
WO2020194087A2 | Extended release pharmaceutical formulation | |
GB201917253D0 | Treatment of conditions | |
GB201907305D0 | Treatment of conditions | |
US2019216740A1 | Extended release pharmaceutical formulation | |
WO2019073408A1 | Extended release pharmaceutical formulation and methods of treatment | |
US2020306194A1 | Extended release pharmaceutical formulation and methods of treatment | |
GB201808567D0 | Pharmaceutical compositions | |
GB201808564D0 | Treatments | |
GB201808571D0 | Pharmaceutical compositions | |
US2019105276A1 | Extended release pharmaceutical formulation | |
CA2849881A1 | Pharmaceutical methods and topical compositions containing acitretin | |
NZ527142A | A stable suspension formulation |